20-F: Enlivex Reports $1.2B Net Income Driven by Crypto Assets; Advances Osteoarthritis Therapy

Enlivex Therapeutics Ltd. reported a significant net income of $1.236 billion for 2025, primarily due to unrealized gains from its digital asset treasury, while advancing its Allocetra osteoarthritis therapy to Phase IIb.

Summary

• Enlivex Ltd. (formerly Enlivex Therapeutics Ltd.) reported a net income of $1.236 billion for the year ended December 31, 2025, a substantial increase from a net loss of $15.014 million in 2024.
• The net income was primarily driven by an aggregate unrealized, non-cash gain of $1.631 billion from increases in the fair value of the company's digital asset treasury and a treasury-related derivative asset (RAIN Option).
• The company maintains a dual strategy combining clinical development of Allocetra for inflammatory conditions, primarily osteoarthritis, with a treasury model anchored in decentralized prediction markets infrastructure through the RAIN protocol.
• Clinical operations continue to incur operating losses, with $9.204 million in research and development expenses (net) and $5.796 million in general and administrative expenses for 2025.
• Positive six-month efficacy data from the Phase IIa trial of Allocetra in moderate to severe knee osteoarthritis (patients aged 60+) showed substantial and durable reductions in pain and improvements in function.
• The company is preparing to commence a Phase IIb global, multicenter, randomized, double-blind, placebo-controlled trial for age-related primary knee osteoarthritis, with FDA clearance for the IND application received in March 2026.
• The sepsis clinical program is seeking external collaborations or out-licensing opportunities for continued development due to limited cash availability and substantial budget requirements.
• The company's digital asset treasury, established in November 2025, had a fair value of $606.781 million as of December 31, 2025, primarily consisting of RAIN tokens.
• An exclusive option to purchase up to 278,181,818,181 RAIN tokens at $0.0033 per token (the RAIN Option) had a fair value of $1.709 billion as of December 31, 2025, and was extended to December 31, 2027.
• In March 2026, the company partially exercised the RAIN Option to acquire an additional 3,030,303,030 RAIN tokens for $10 million.
• The company completed a private placement in November 2025, raising $212 million in gross proceeds, primarily used to purchase RAIN tokens.
• A Senior Secured Convertible Promissory Note of $21.0 million was issued to Lind Global Asset Management XIV, LLC in March 2026, providing $19.0 million in net proceeds, secured by certain digital assets including RAIN tokens.
• The company authorized a share repurchase program for up to $20 million of ordinary shares in March 2026, to be funded with proceeds from the Lind transaction.
• The company initiated the process to voluntarily delist its ordinary shares from the Tel Aviv Stock Exchange (TASE), with delisting expected around April 26, 2026.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development due to the substantial net income and promising clinical trial results for Allocetra in osteoarthritis. However, the reliance on volatile digital asset gains for profitability and ongoing operating losses from core R&D introduce significant risk and uncertainty.

Positives

• Reported a net income of $1.236 billion for 2025, a significant turnaround from previous losses, primarily driven by digital asset gains.
• Allocetra Phase IIa trial in moderate to severe knee osteoarthritis showed substantial and durable reductions in pain and improvements in function in the primary age group (60+).
• Received FDA clearance for the Investigational New Drug (IND) application for the Phase IIb trial of Allocetra in age-related primary knee osteoarthritis in the United States.
• Successfully established a digital asset treasury strategy with significant holdings in RAIN tokens and a valuable RAIN Option, contributing substantially to the company's asset base.
• The RAIN Option, allowing purchase of a large quantity of RAIN tokens at a fixed price, was extended to December 31, 2027, indicating continued strategic flexibility in digital asset management.
• Successfully raised $19.0 million in net proceeds through a Senior Secured Convertible Promissory Note, providing additional capital for operations.
• Authorized a share repurchase program of up to $20 million, signaling confidence in the company's valuation and financial position.

Negatives

• Clinical operations continue to incur significant operating losses, with $15.029 million operating loss in 2025, indicating that core therapeutic development is not yet profitable.
• The ability to continue operating as a going concern is dependent on additional financial support, with existing resources projected to last only through the end of 2027.
• The sepsis clinical program is being pursued through external collaborations or out-licensing due to limited cash availability and substantial budget requirements, indicating internal resource constraints for this indication.
• The significant net income is primarily from unrealized, non-cash gains on digital assets, which are highly volatile and may not be indicative of sustainable operating performance or cash flows.
• The company's digital asset treasury strategy is untested and subject to significant volatility, regulatory uncertainty, and liquidity risks associated with cryptocurrency markets.
• The concentration of cryptocurrency holdings in RAIN tokens enhances inherent risks, as a significant decline in RAIN's value would have a pronounced impact on financial condition.
• The company's historical financial statements may not be indicative of future results due to the volatility of digital cryptocurrency assets.

Risks

• The company's dual strategy, combining clinical development and a cryptocurrency treasury model, is subject to the inherent risks of both highly volatile sectors.
• Clinical operations are expected to incur additional losses and may never achieve or maintain operating profitability.
• The company has not generated any revenue from Allocetra or any other product candidate and may never be profitable from clinical operations.
• Substantial additional capital will be needed in the future to support clinical operations, and if not available, development may be delayed, reduced, or ceased.
• There is no guarantee that Allocetra or any other product candidate will achieve commercial success in a timely and cost-effective manner, or ever.
• Clinical trial results may be negative or may not replicate earlier results, potentially requiring abandonment of product development.
• The clinical trial process is complex, expensive, and prone to delays or prevention due to regulatory hurdles, recruitment challenges, or unforeseen safety issues.
• Manufacturing processes for Allocetra are complex, delicate, susceptible to contamination, and involve biological intermediates subject to stringent regulations, posing risks of product shortages, recalls, or increased costs.
• Even if Allocetra receives marketing approval, it will face extensive ongoing regulatory requirements and potential future development and regulatory difficulties.
• Sales of approved products will be limited unless broad market acceptance is achieved, which depends on factors like reimbursement, physician acceptance, and competition.
• Significant disruptions of information technology systems, cyberattacks, and other security breaches could compromise proprietary information, harming business and reputation.
• The company is highly dependent on a small number of senior executive officers, and the loss of their services could adversely affect business execution.
• Reliance on third parties to conduct clinical trials and potentially to market and sell products introduces risks of delays, quality issues, and reduced control over commercialization efforts.
• Failure to obtain or maintain patents, licensing agreements, and other intellectual property could impact the ability to compete effectively.
• The prices of digital assets, including RAIN, are highly volatile, and fluctuations can significantly impact operating results and share price.
• Cryptocurrency holdings are less liquid than cash and cash equivalents and may not serve as a reliable source of liquidity during market instability.
• Regulatory developments related to cryptocurrency and digital asset markets are uncertain and could adversely affect the business, financial condition, and results of operations, potentially leading to extensive regulation or operational shutdowns.
• The classification of digital assets as securities could subject the company to significant additional regulatory requirements under the Investment Company Act of 1940, potentially forcing operational changes or cessation.
• Regulatory risks of operating a prediction market, such as the RAIN protocol, are extensive and could lead to litigation, enforcement actions, or criminal risks if deemed an illegal gambling or unregistered money services business.
• Security breaches or cyberattacks affecting digital asset custodians, or loss of private keys, could result in the loss of some or all of the company's cryptocurrency holdings.
• The company is exposed to counterparty risk with third-party service providers in its digital asset strategy, including custodians and liquidity providers.
• The launch of central bank digital currencies (CBDCs) may adversely impact the value of digital asset treasuries.
• Intellectual property disputes related to open-source digital asset networks and the irreversibility of digital asset transactions pose additional risks.
• Changes in tax treatment of staking digital assets could lead to additional tax liability, interest, and penalties.
• The company is not subject to legal and regulatory obligations that apply to investment companies or investment advisers, which may provide less investor protection.
• Political, economic, and military instability in Israel, where the company's headquarters and significant operations are located, could adversely affect business and operations.
• Exchange rate fluctuations between the U.S. dollar, Euro, and NIS may negatively affect earnings.
• Obligations to the Israel Innovation Authority (IIA) for past grants restrict technology transfer and manufacturing outside of Israel, potentially requiring increased royalties or payments.
• Provisions of Israeli law and the company's articles of association, including a staggered board, may delay, prevent, or impede a merger or acquisition.

Future Outlook

The company anticipates continued significant operating losses from its clinical operations for the foreseeable future and will require substantial additional financing beyond 2027. It plans to initiate a Phase IIb global, multicenter, randomized, double-blind, placebo-controlled trial for age-related primary knee osteoarthritis, with three and six-month topline data expected in Q2 and Q3 2027, respectively. The sepsis clinical program will seek external collaborations or out-licensing. The digital asset treasury strategy aims to enhance returns through various DeFi strategies, though their availability and success are not assured. The company expects to fund future operations through equity/debt financings or out-licensing. The voluntary delisting from the TASE is expected around April 26, 2026.

Management Comments

• "We are a quality longevity company focused on advancing therapies designed to extend health span and quality of life, powered by a prediction markets treasury."
• "AllocetraTM is a universal, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state, which is critical for immune system rebalancing and the resolution of inflammatory conditions."
• "We are the first publicly listed company to have developed a treasury strategy centered on the RAIN token, which currently serves as the Companys primary treasury reserve asset."
• "In adopting our treasury policy, we intend to provide investors with exposure to prediction markets through RAIN and to advocate for its role as digital capital."
• "We believe that RAIN has long-term utility, scarcity characteristics through its deflationary buyback and burn mechanism, and potential ecosystem growth prospects."
• "Management and the Board of Directors believe that the Company has sufficient resources to fund its operations for at least twelve months following the date of filing of these financial statements with the SEC."

Industry Context

StockSavvy.ai notes that Enlivex's dual strategy is highly unconventional, combining a clinical-stage biotech's traditional R&D with a significant, volatile digital asset treasury. While the biotech sector faces high R&D costs and long development cycles, the integration of a cryptocurrency treasury, particularly one focused on a prediction markets token like RAIN, introduces a novel and high-risk/high-reward element. This approach aims to provide alternative funding and investor exposure to emerging digital markets, differentiating Enlivex from traditional biotech peers. The positive Phase IIa osteoarthritis data positions Allocetra competitively in a large unmet medical need, but the shift of the sepsis program to external collaboration highlights the capital intensity of drug development. The company's substantial net income, driven by digital asset revaluation, contrasts sharply with the ongoing operating losses from its core clinical activities, underscoring the speculative nature of its current financial performance relative to its therapeutic mission.

Comparison to Industry Standards

• Enlivex's dual strategy of combining clinical-stage biotech with a significant digital asset treasury is highly atypical compared to global biotech industry standards, which typically focus solely on drug development and traditional financial instruments.
• The reported net income of $1.236 billion for 2025, primarily from unrealized gains on digital assets, is not comparable to the operating profitability metrics of established pharmaceutical or biotech companies like Pfizer or Johnson & Johnson, which derive revenue from product sales.
• The positive Phase IIa data for Allocetra in moderate to severe knee osteoarthritis (age 60+ group) is a promising clinical milestone, comparable to early-to-mid-stage clinical successes seen in other biotech firms developing therapies for chronic inflammatory conditions, such as Regeneron's Eylea or AbbVie's Humira in their respective development stages.
• The decision to seek external collaboration for the sepsis program due to budget constraints is a common strategy for smaller biotech companies, similar to how many early-stage firms partner with larger pharmaceutical companies to fund expensive Phase III trials or commercialization efforts.
• The company's reliance on a single digital asset (RAIN) for a substantial majority of its treasury assets introduces a concentration risk far exceeding the diversified, low-volatility treasury management practices of most public companies, including those in the biotech sector.
• The volatility of RAIN and the regulatory uncertainty surrounding digital assets and prediction markets present risks that are not typically encountered by traditional biotech companies, making direct comparisons to industry-standard risk profiles challenging.

Management Changes

Corporate Governance

Legal Proceedings

• The company is involved in various routine legal proceedings incidental to the ordinary course of business, but does not currently believe the outcome will have significant effects on its financial position or profitability.
• Litigation is subject to inherent uncertainties, and adverse results could harm the company's business.

Related Party Transactions

• Research agreement with Cell Generation (C-G) Ltd., where Prof. Dror Mevorach (former Chief Science & Medical Officer) serves as principal investigator. The company paid a non-refundable advance of NIS 430,000 and is obligated for collection, screening, and recruitment remuneration.
• Employment and consulting agreements with Executive Chairman, Chief Executive Officer, Chief Financial Officer, and Chief Medical Officer, including non-competition, confidentiality, and invention assignment provisions.
• Executive Chairman's consulting agreement entitles him to 3.33% of future gross proceeds from commercial transactions or company sale, payable once aggregate consideration exceeds $20 million.
• Indemnification agreements with directors and officers, exculpating them from duty of care liability and indemnifying them to the fullest extent permitted by Israeli law, with coverage limits.
• Directors and officers liability insurance obtained with maximum coverage of $10 million (aggregate) and additional Side A coverage of $40 million (aggregate).
• Granted options and restricted share units to executive officers and directors under equity incentive plans.

Stakeholder Impact

• **Shareholders**: Significant unrealized gains from digital assets have led to a substantial increase in reported net income and retained earnings, potentially boosting shareholder value. However, the high volatility and regulatory uncertainty of digital assets, along with ongoing operating losses from clinical operations, introduce considerable risk to future share price and investment returns. The share repurchase program could benefit shareholders by reducing outstanding shares.
• **Employees**: The company continues to invest in research and development, supporting employment in clinical operations. Share-based compensation plans provide incentives. Political and military instability in Israel could disrupt operations and impact employee safety or availability.
• **Customers/Patients (future)**: Positive Phase IIa clinical trial results for Allocetra in osteoarthritis offer hope for a new therapeutic option for patients with moderate to severe knee osteoarthritis. The pursuit of Phase IIb trials indicates continued commitment to bringing this therapy to market.
• **Creditors**: The issuance of a Senior Secured Convertible Promissory Note to Lind Global Asset Management XIV, LLC, secured by digital assets, impacts the company's debt profile and asset collateralization. The company's ability to meet obligations depends on future financing and the success of its dual strategy.
• **Suppliers/Partners**: Reliance on third-party CROs, CMOs, and blood banks for clinical trials and manufacturing means their performance and compliance are critical to the company's progress. The shift of the sepsis program to external collaboration indicates potential opportunities for new partners.

Next Steps

• Commence a Phase IIb global, multicenter, randomized, double-blind, placebo-controlled trial for age-related primary knee osteoarthritis.
• Expect three-month topline data from the Phase IIb osteoarthritis trial in Q2 2027.
• Expect six-month topline data from the Phase IIb osteoarthritis trial in Q3 2027.
• Seek potential external collaborations or out-licensing opportunities for the continued clinical development of Allocetra for use in patients with sepsis.
• Voluntarily delist ordinary shares from the Tel Aviv Stock Exchange (TASE) by approximately April 26, 2026.
• Potentially utilize various capital markets and on-chain strategies (staking, restaking, liquid staking, DeFi protocols) to enhance returns on RAIN holdings.
• File a registration statement (Lind Registration Statement) with the SEC on or prior to April 22, 2026, for the resale of shares related to the Lind Note.

Key Dates

Recommendation

The company's financial results for 2025 show a dramatic increase in net income, primarily driven by unrealized gains from its digital asset treasury. This, coupled with promising Phase IIa clinical data for Allocetra in osteoarthritis and the progression to Phase IIb, presents a compelling upside. However, the core clinical operations continue to incur significant losses, and the digital asset strategy, while lucrative in 2025, is inherently highly volatile and subject to substantial regulatory and market risks. The company's long-term viability still hinges on successful clinical development and commercialization, which requires significant additional funding. Given the speculative nature of the digital asset gains and the ongoing R&D expenses, a 'hold' recommendation is appropriate. Investors should monitor the progress of Allocetra's Phase IIb trials and the stability of the digital asset market, as both will be critical determinants of future value.

Keywords

Allocetra, Osteoarthritis, Cell Therapy, Immunotherapy, RAIN Protocol, Digital Assets, Cryptocurrency, Prediction Markets, SEC Filing, Biotechnology, Clinical Trials, Phase IIb, Treasury Strategy, ENLV, Nasdaq Capital Market, Israel Innovation Authority, Corporate Governance, Risk Management, Financial Reporting